ÂÜÀòÂÒÂ×

Ross Pettit has extensive experience in the pharmaceutical and biotech industry. Ross has held various leadership roles throughout their career, starting as a CRA III at Otsuka America, Inc. in 1994. Ross then went on to work at EMD Serono as an Associate Director of Regulatory Affairs before joining Coley Pharmaceutical Group, where they served as a Senior Director of Global Clinical Development and later as a VP of Clinical Operations. Pettit then joined ARIAD Pharmaceuticals as a VP of Clinical Operations before moving to AMAG Pharmaceuticals as a Vice President of Clinical Operations. Ross continued to advance their career at Infinity Pharmaceuticals and BeiGene, where they held the positions of Senior Vice President of Development Operations. Ross then joined H3 Biomedicine, serving in multiple roles including Deputy President, Senior Vice President of Corporate Strategy & Operations, and Vice President of Clinical Development Operations. Pettit's most recent positions include Chief Operating Officer at CHARM Therapeutics and SVP, Head of Development Operations at Kestrel Therapeutics.

Ross Pettit attended Kingston University, where they obtained a Bachelor of Science degree in Applied Sciences. Ross later pursued a Master of Business Administration (MBA) in Healthcare Management at the University of Phoenix from 2003 to 2005. Ross also attended CGS from 1980 to 1982, although specific degree and field of study information was not provided.